Literature DB >> 16206368

Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT.

Désirée van der Heijde1, Robert Landewé.   

Abstract

Radiographs are important for assessing structural damage in patients with ankylosing spondylitis (AS); this technology was selected by the international ASsessment in Ankylosing Spondylitis (ASAS) Working Group as an important domain for assessing outcome in clinical trials. The selection of a preferred scoring method based on the OMERACT filter still needs to be undertaken. This article describes the scientific basis for and process of making the selection. Finally, both the ASAS Working Group and OMERACT participants voted for the modified Stoke AS Spinal Score (mSASSS) as the preferred scoring method for use in clinical trials in AS.

Entities:  

Mesh:

Year:  2005        PMID: 16206368

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  16 in total

Review 1.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 2.  Radiographic Progression in Ankylosing Spondylitis: From Prognostication to Disease Modification.

Authors:  Ismail Sari; Nigil Haroon
Journal:  Curr Rheumatol Rep       Date:  2018-11-08       Impact factor: 4.592

Review 3.  Clinical assessment and outcome research in spondyloarthritis.

Authors:  Robert B M Landewé; Astrid van Tubergen
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

4.  Effect of Therapy on Radiographic Progression in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.

Authors:  Paras Karmacharya; Ali Duarte-Garcia; Maureen Dubreuil; M Hassan Murad; Ravi Shahukhal; Pragya Shrestha; Elena Myasoedova; Cynthia S Crowson; Kerry Wright; John M Davis
Journal:  Arthritis Rheumatol       Date:  2020-04-01       Impact factor: 10.995

Review 5.  Tools for monitoring spondyloarthritis in clinical practice.

Authors:  Astrid M van Tubergen; Robert B M Landewé
Journal:  Nat Rev Rheumatol       Date:  2009-10-06       Impact factor: 20.543

6.  Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

Authors:  M Dougados; J Braun; S Szanto; B Combe; M Elbaz; P Geher; G Thabut; V Leblanc; I Logeart
Journal:  Ann Rheum Dis       Date:  2011-02-13       Impact factor: 19.103

7.  Bone morphogenetic protein 6 polymorphisms are associated with radiographic progression in ankylosing spondylitis.

Authors:  Young Bin Joo; So-Young Bang; Tae-Hwan Kim; Seung-Cheol Shim; Seunghun Lee; Kyung Bin Joo; Jong Heon Kim; Hye Joon Min; Proton Rahman; Robert D Inman
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

8.  Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.

Authors:  Désirée van der Heijde; David Salonen; Barbara N Weissman; Robert Landewé; Walter P Maksymowych; Hartmut Kupper; Shaila Ballal; Eric Gibson; Robert Wong
Journal:  Arthritis Res Ther       Date:  2009-08-24       Impact factor: 5.156

9.  Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?

Authors:  Sofia Ramiro; Astrid van Tubergen; Carmen Stolwijk; Robert Landewé; Filip van de Bosch; Maxime Dougados; Désirée van der Heijde
Journal:  Arthritis Res Ther       Date:  2013-01-17       Impact factor: 5.156

10.  Evaluation of treatments for sacroiliitis in spondyloarthropathy using the Spondyloarthritis Research Consortium Canada scoring system.

Authors:  Yang Cui; Jinping Zheng; Xiao Zhang; Hui Zeng; Riqiang Luo
Journal:  Arthritis Res Ther       Date:  2016-02-01       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.